Clinical Trials · NCT03209518
Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Takeda
- Enrollment
- 312
- Start date
- Mar 2016
- Locations
- 1 site, Japan
- Primary endpoint
- Percentage of Participants Who Had One or More Adverse Events